公开(公告)号：AT147678T

公开(公告)日：1997-02-15

申请号：AT92921233

申请日：1992-09-25

Applicant: BAXTER INT

Inventor： WOO LECON ,  LO YING ,  LING MICHAEL R K ,  LAURIN DEAN ,  GLEASON BYRON ,  BUAN LILLIAN A ,  JOHNSTON WILLIAM D

IPC: A61J1/10 ,  B29C65/00 ,  B29C65/04 ,  B29C65/52 ,  B29L9/00 ,  B29L22/00 ,  B32B7/02 ,  B65D65/42 ,  B65D75/30 ,  A61M1/14

Abstract: The coating of a RF active material on a non-RF active substrate material of typical thickness for packaging purposes, can generate sufficient thermal energy to effect strong bonding of the substrate materials. The RF active material may be-deposited on less than the entire inner surface area of the substrate material, preferably, at or near the portion of the substrate surface which represents the heat seal interface. In this manner of application, additional coating or printing of other substances on the substrate surface can be achieved without hampering the heat sealing process. Flexible medical containers capable of containing a product which is maintained and removed under sterile conditions, can be constructed on commercial production machines from these coated non-RF active substrate materials.

公开(公告)号：CA2132016A1

公开(公告)日：1994-10-14

申请号：CA2132016

申请日：1993-03-25

Applicant: BAXTER INT

Inventor： BRAUKER JAMES H ,  HILL RONALD S ,  JOHNSON ROBERT C ,  MARTINSON LAURA A ,  JOHNSTON WILLIAM D

IPC: A61F2/02 ,  A61K9/00 ,  A61L27/38 ,  A61L27/00

Abstract: 2132016 9319701 PCTABS00027 Implant assemblies (10) and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary between the host and the implanted cells (12). The boundary has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells (12) during the critical ischemic period and afterward. The boundary allows the fabrication and clinical use of implant assemblies and methodologies that can carry enough cells (12) to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host.

公开(公告)号：ES2167332T3

公开(公告)日：2002-05-16

申请号：ES93908495

申请日：1993-03-25

Applicant: BAXTER INT

Inventor： BRAUKER JAMES H ,  HILL RONALD S ,  JOHNSON ROBERT C ,  MARTINSON LAURA A ,  JOHNSTON WILLIAM D

IPC: A61F2/02 ,  A61K9/00 ,  A61L27/38 ,  A61L27/00 ,  C12N5/00

Abstract: Implant assemblies (10) and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary between the host and the implanted cells (12). The boundary has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells (12) during the critical ischemic period and afterward. The boundary allows the fabrication and clinical use of implant assemblies and methodologies that can carry enough cells (12) to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host.

公开(公告)号：PT676935E

公开(公告)日：2002-04-29

申请号：PT93908495

申请日：1993-03-25

Applicant: BAXTER INT

Inventor： HILL RONALD S ,  MARTINSON LAURA A ,  JOHNSON ROBERT C ,  BRAUKER JAMES H ,  JOHNSTON WILLIAM D

IPC: A61F2/02 ,  A61K9/00 ,  A61L27/38 ,  A61L27/00 ,  C12N5/00

Abstract: Implant assemblies (10) and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary between the host and the implanted cells (12). The boundary has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells (12) during the critical ischemic period and afterward. The boundary allows the fabrication and clinical use of implant assemblies and methodologies that can carry enough cells (12) to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host.

公开(公告)号：NO970054A

公开(公告)日：1997-03-10

申请号：NO970054

申请日：1997-01-07

Applicant: BAXTER INT

Inventor： GELLER ROBIN LEE ,  BRAUKER JAMES H ,  JOHNSTON WILLIAM D ,  LEVON STEVEN A ,  MARYANOV DAVID A

IPC: A61K9/00 ,  A61K35/12 ,  A61K35/13 ,  A61K38/00 ,  A61K38/19 ,  A61K39/00 ,  A61P35/00 ,  C12N5/08 ,  A61K39/385 ,  A61K39/39

CPC classification number: A61K9/0024 ,  A61K35/13 ,  A61K38/19 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2300/00

Abstract: An implantable device for the prevention or treatment of cancer comprising an implantable chamber containing tumor cells, or somatic cells engineered to express at least one antigen corresponding to antigen of a patient's tumor; the chamber having a porous wall to provide, in use, a porous boundary between the patient's immune cells and the contained cells; the porosity of the boundary being sufficient to permit subcellular antigenic material to pass through the boundary, while preventing the contained cells and patient immune cells from passing through the boundary.

公开(公告)号：CA2194555A1

公开(公告)日：1996-01-25

申请号：CA2194555

申请日：1995-06-29

Applicant: BAXTER INT

Inventor： MARYANOV DAVID A ,  BRAUKER JAMES H ,  JOHNSTON WILLIAM D ,  GELLER ROBIN LEE ,  LEVON STEVEN A

IPC: A61K9/00 ,  A61K35/12 ,  A61K35/13 ,  A61K38/00 ,  A61K38/19 ,  A61K39/00 ,  A61P35/00 ,  A61M37/00 ,  A61K38/17

Abstract: An implantable device for the prevention or treatment of cancer comprising a n implantable chamber containing tumor cells, or somatic cells engineered to express at least one antigen corresponding to antigen of a patient's tumor, the chamber having a porous wall to provide, in use, a porous boundary between the patient's immune cells and the contain ed cells; the porosity of the boundary being sufficient to permit subcellular antigenic material to pass through the boundary, while preventin g the contained cells and patient immune cells from passing through the boundary.